Sodium iodide symporter-based strategies for diagnosis and treatment of thyroidal and nonthyroidal malignancies.
The recent cloning and molecular characterization of the sodium iodide-symporter (NIS) has inspired novel approaches to the diagnosis and treatment of thyroidal and nonthyroidal malignancies. This article briefly reviews the physiologic regulation of NIS expression by cytokines, the expression in benign and malignant thyroidal diseases, and the expression in extrathyroidal tissues. Current concepts for NIS-based cancer therapy in thyroidal and extrathyroidal tumors are presented. The recent discovery of NIS expression in a majority of breast cancers as well as its promising application for prostate cancer imply potential applications in diagnostic imaging and radioiodine anticancer therapy for these highly common and lethal malignancies.
Heufelder
A E
AE
Department of Internal Medicine, Philipps-University, Marburg, Germany. endoc@web.de
Morgenthaler
N
N
Schipper
M L
ML
Joba
W
W
D000818:Animals; D001943:Breast Neoplasms / Q000175:diagnosis / Q000628:therapy; D005260:Female; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000628:therapy; D027981:Symporters / Q000378:metabolism*; D013961:Thyroid Gland / Q000378:metabolism*; D013964:Thyroid Neoplasms / Q000175:diagnosis* / Q000628:therapy*; D000099209:Sodium-Iodide Symporters
D027981:Symporters; D000099209:Sodium-Iodide Symporters